- FDA advisory panel to consider OTC status of NSAIDs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
WAYNE, N.J. — The Food and Drug Administration has approved a new oral contraceptive developed by Bayer.
Safyral is a combination of Yasmin, also developed by Bayer, with 451 mcg levomefolate calcium, which is a B vitamin known as a folate. It is the second oral contraceptive from Bayer that features folate.
"With the FDA approval of Safyral, Bayer now offers two oral contraceptives that contain folate," said Leslie North, VP women's healthcare marketing at Bayer HealthCare Pharmaceuticals. "Safyral and Beyaz are part of Bayer's growing women's health franchise, and these new products reinforce our commitment to providing women various contraceptive options."